Merck’s CEO to succeed Ken Frazier as chairman

Reuters

(Reuters) – Merck & Co said on Wednesday Chief Executive Officer Rob Davis would succeed Chairman Ken Frazier, taking on the additional role effective Dec. 1.

Frazier, who has been a key growth driver of the drugmaker for decades, joined Merck around 30 years ago and became the first Black CEO of a major drug company in 2011.

He has steered the company through the daunting litigation tied to withdrawn painkiller Vioxx, and also played a key role in Merck’s 2009 acquisition of U.S. drugmaker Schering-Plough, picking up what would become the company’s top-selling drug, Keytruda.

Related News:   SARA FRANKENSTEIN: Illinois Task Force Hearing Exposes Ranked-Choice Voting as a Power Grab by Liberal Elites

Frazier made headlines in 2017 when he became the first business leader to leave former U.S. President Donald Trump’s manufacturing council following Trump’s comments on a white nationalist rally held in Charlottesville, Virginia.


(Reporting by Khushi Mandowara and Michael Erman in New Jersey; Editing by Shinjini Ganguli)


tagreuters.com2022binary_LYNXMPEI9P0UI-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.